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Abstract
Background: The present study was conducted to analyze the value of ([18F] fluoromisonidazole
(FMISO) and [18F]-2-fluoro-2'-deoxyglucose (FDG) PET as well as color pixel density (CPD) and
tumor perfusion (TP) assessed by color duplex sonography (CDS) for determination of therapeutic
relevant hypoxia. As a standard for measuring tissue oxygenation in human tumors, the invasive,
computerized polarographic needle electrode system (pO2 histography) was used for comparing
the different non invasive measurements.
Methods: Until now a total of 38 Patients with malignancies of the head and neck were examined.
Tumor tissue pO2 was measured using a pO2-histograph. The needle electrode was placed CT-
controlled in the tumor without general or local anesthesia. To assess the biological and clinical
relevance of oxygenation measurement, the relative frequency of pO2 readings, with values ≤ 2.5,≤ 5.0 and ≤ 10.0 mmHg, as well as mean and median pO2 were stated. FMISO PET consisted of one
static scan of the relevant region, performed 120 min after intravenous administration. FMISO
tumor to muscle ratios (FMISOT/M) and tumor to blood ratios (FMISOT/B) were calculated. FDG
PET of the lymph node metastases was performed 71 ± 17 min after intravenous administration.
To visualize as many vessels as possible by CDS, a contrast enhancer (Levovist®, Schering Corp.,
Germany) was administered. Color pixel density (CPD) was defined as the ratio of colored to grey
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BMC Cancer 2007, 7:113 http://www.biomedcentral.com/1471-2407/7/113pixels in a region of interest. From CDS signals two parameters were extracted: color hue –
defining velocity (v) and color area – defining perfused area (A). Signal intensity as a measure of
tissue perfusion (TP) was quantified as follows: TP = vmean × Amean.
Results: In order to investigate the degree of linear association, we calculated the Pearson
correlation coefficient. Slight (|r| > 0.4) to moderate (|r| > 0.6) correlation was found between the
parameters of pO2 polarography (pO2 readings with values ≤ 2.5, ≤ 5.0 and ≤ 10.0 mmHg, as well
as median pO2), CPD and FMISOT/M. Only a slight correlation between TP and the fraction of pO2
values ≤ 10.0 mmHg, median and mean pO2 could be detected. After exclusion of four outliers the
absolute values of the Pearson correlation coefficients increased clearly. There was no relevant
association between mean or maximum FDG uptake and the different polarographic- as well as the
CDS parameters.
Conclusion: CDS and FMISO PET represent different approaches for estimation of therapy
relevant tumor hypoxia. Each of these approaches is methodologically limited, making evaluation of
clinical potential in prospective studies necessary.
Background
Tumor hypoxia has been associated with malignant pro-
gression, representing an increasing probability of recur-
rence, loco regional spread and distant metastases. In
addition, the hypoxic fraction in solid tumors reduces
their sensitivity to conventional treatment modalities,
modulating therapeutic response to ionizing radiation or
certain chemotherapeutic agents [5,8,10,25]. Conse-
quently detection and monitoring of tissue oxygenation
can be important for modifying therapeutic strategies,
including local dose escalation for radiotherapy or selec-
tion of chemotherapeutic agents with better impact even
in hypoxic tumors. The causes of tumor hypoxia are com-
plex including multiple factors determining tumor blood
flow such as perfusion pressure, viscous and geometric
resistance to flow, arteriovenous shunts and interstitial
fluid flow.
Numerous different approaches have been made to iden-
tify hypoxia in tumors [12,13]. The computerized polaro-
graphic needle electrode system (pO2 histography)
represents one standard for measuring tissue oxygenation
in human malignancies [28]. However, it is an invasive
method being confined to superficial, well accessible
tumors or lymph node metastases.
A non-invasive approach to detect hypoxia in tumors is
the positron emission tomography (PET) with nitroimi-
dazole derivates. Nitroimidazoles are recognized to bind
selectively to hypoxic cells [23] and are reduced intracel-
lular. In hypoxic cells re-oxidation is hindered, leading to
intracellular accumulation of nitroimidazole. Radiola-
belled nitroimidazole used in positron emission tomogra-
phy is therefore highly suitable to determine tumor tissue
oxygenation.
We present the results of our analyses of a cohort of
patients with head and neck malignancies, being exam-
ined with direct, invasive measurements of tissue oxygen-
ation by pO2 polarography and non-invasive [18F]
Fluoromisonidazole (FMISO) and [18F] Fluorodeoxyglu-
cose (FDG) positron-emission-tomography (PET) for
determination of tumor oxygenation. In addition two fac-
tors related to oxygen delivery, the tumor vascularisation
and tumor perfusion were measured by contrast-
enhanced color duplex sonography (CDS).
Methods
Patients
Lymph node metastases of 38 patients with histologically
verified head and neck malignancies (36 patients with
squamous cell cancer, one patient with lympho-epithelial
cancer and one patient with Hodgkin's lymphoma) were
enrolled in a prospective clinical evaluation between
October 2002 and January 2005. Standard sonographic,
CT and PET criteria were used for the diagnosis of meta-
static lymph nodes. In 20 patients the diagnosis were con-
firmed histologically. Patients underwent the following
measurements within one week: contrast-enhanced color
duplex sonography (CDS), FDGPET, FMISOPET and
polarographic pO2 measurement (last measurement).
None of the patients had previously been treated for their
malignancies. Because of different treatment modalities
(surgery followed by radio- or radio-/chemotherapy, pri-
mary radio-/chemotherapy and chemotherapy alone) no
clinical analysis was performed. The study was approved
by the medical ethical committee of the University
Aachen, Germany. After explanation of the rationale,
risks, and benefits of the examination, informed consent
was obtained from all patients.
Measurements were performed in one lymph node metas-
tases in each patient. In order to ensure measurements inPage 2 of 9
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ined lymph nodes were marked on diagnostic CT scans or
in the case of lymph node conglomerates, the extension of
the scanned node was marked on skin. PET examinations
were realized in most of the patients within two days
(maximum time interval four days) using skin markers
and positioning lasers for reproducible data acquisition
resulting in a corresponding slice location. No immobili-
zation device was used. Sonographic studies, selection of
representative images and parameter calculation as well as
polarographic measurement were performed by one per-
son each respectively, resulting in an objective and inde-
pendent data acquisition. As detailed information of all
used techniques was published by our group [3,6,27,34]
only a description of the essential aspects of the different
measurement procedures is given.
Color Duplex Sonograpy (CDS)
Technical details and adjustment of the sonography
device were used as previously published [3,6,27]. In
order to visualize as many vessels as possible a contrast
enhancer (Levovist, Schering Corp., Berlin, Germany) was
administered. We used a solution of 4 g Levovist® in 11 ml
sterile water for injection. 5.5 ml were given as a bolus
whereas 5.5 ml were infused with 300 ml/h. CDS was per-
formed in 32 patients.
Color pixel density (CPD)
This examination could be realized in 32 patients. All
sonographic studies were recorded on digital video. From
these video recordings, representative horizontal and lon-
gitudinal scans were selected for assessment. Depending
on the size of the investigated nodes, this resulted in 5 to
16 (mean = 8.13;standard deviation (SD) = 4.38) images
of each lymph node. For visualization of tumor vasculari-
sation, the maximal systolic phases were used. Sono-
graphic studies, selection of representative images and
parameter calculation were performed by one person
each, respectively. In a region of interest, representing the
extent of vascularisation in the investigated slice, CPD was
defined as ratio of colored pixels to gray pixels. The mean
CPD was calculated in order to find a representative value
for imaged vascularisation.
Quantification of perfusion
In the course of the study the commercially software (Pix-
elFlux®, Chameleon-Software Corp., Leipzig, Germany)
was available. In 18 patients this software was used for
evaluation of blood flow dynamics in the lymph node
metastases until now. Cervical lymph nodes were exam-
ined at the largest diameter to record perfusion signals of
intranodal vessels. All sonographic studies were recorded
and perfusion signals of every single image were read out
automatically from the region of interest (ROI). The ROI
was defined in advance, encompassing the whole node's
area, sparing out surrounding tissue.
The new technique allows a simultaneous measurement
of the classical resistance index (RI) and pulsatility index
(PI) in all vessels of the region of interest (ROI) [27].
Every single pixel in each vessel is traced through a com-
plete heart cycle. Changes of color hue – representing flow
velocity at this point – are measured and RI as well as PI is
calculated. By this approach tissue-RI (TRI) and tissue-PI
(TPI) for each point of a complete heart cycle were calcu-
lated, representing mean PI and RI of all vessels inside the
ROI. Signal intensity as a measure of tissue perfusion (TP)
was quantified as follows: TP = vmean × Amean with A = part
of the ROI filled with color signals and v = velocity values
of all pixels inside the ROI changing due to heart action.
Positron-Emission-Tomography (PET)
In 24 patients FDG PET as well as FMISO PET examina-
tions could be performed. All PET studies were carried out
using an ECAT EXACT 922/47® scanner with an axial field
of view of 16.2 cm (Siemens CTI, Knoxville, TN, USA).
The spatial resolution in the transaxial and axial orienta-
tion of this PET is nearly isotopic. In the reconstructed
images, the full width at half maximum (FWHM) is about
6.0 mm measured at the center of the field of view (FOV)
using a ramp filter with a 0.5 cut-off frequency.
FDG PET of the tumor region was performed 71 ± 17 min
after intravenous administration of 264 ± 46 MBq FDG,
applying the whole-body tool with 8 min emission scan-
ning and 4 min transmission scanning for each bed posi-
tion. After correction for attenuation using the
transmission scan optimized by a segment µ-map with
empirical attenuation coefficients, the data were recon-
structed with the OSEM algorithm [14]. All patients fasted
for at least 6 h before examination, verified by determin-
ing blood glucose level (mean = 90.8 mg/dl; SD = 16.0
mg/dl). None of the patients showed a higher concentra-
tion than 120 mg/dl, so treatment with insulin prior to
examination was not necessary.
FMISO PET consisted of one static scan of the relevant
region – as defined by sonography or computed tomogra-
phy – performed 120 min after intravenous administra-
tion of 314 ± 42 MBq FMISO. The acquisition time
included 15 min emission scanning followed by 4 min
transmission scanning. Attenuation correction and recon-
struction processing was done according to FDG PET.
Three venous blood samples (after 120-, 125- and 130
minutes) were taken at each static scan. After correction
according to the half-life period the mean values were cal-
culated. The radioactivity concentration was measured in
a calibrated well counter (Spectrum Master 92X, EG&GPage 3 of 9
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mean values were calculated.
The tumor was defined according to the image data of the
FDG-PET and the puncture computer tomography (CT)
scans. In cases where the tumour was not clearly visible in
the FMISO scan, FDG data were used to delineate the
malignant lesion and define a region of interest. Rectan-
gular regions of interest depending to the tumor size were
placed over the tumor and ipsilateral nuchal muscles in
order to calculate FMISO tumor to muscle ratios (FMISOT/
M). To calculate tumor to blood ratios (FMISOT/B) at 120
min after administration of FMISO, the average radioac-
tivity concentration of the three blood samples was used.
For FDG PET, mean and maximum standardized uptake
values (SUV) of the tumor were calculated after normali-
zation of the radioactivity concentration to the injected
radioactivity and the body weight. Additionally, the mean
SUV was approximately corrected for partial volume
effects by applying recovery coefficients obtained from
phantom studies [14]...
Polarographic pO2 measurement
Tumor oxygenation was measured in 36 patients with
polarographic needle electrodes, using a pO2-histograph
(Eppendorf, Hamburg, Germany). Sterile polarographic
needle electrodes with stainless steel shafts and a mean
diameter of 300 µm were used. For each patient the needle
electrodes were placed and guided CT-controlled in the
tumor after visual matching of CT- and PET-scans without
general or local anesthesia, avoiding larger necrotic areas
by preceding diagnostic CT scans. In this way we realized
95–400 single pO2 measurements per lymph node (mean
= 225; SD = 61) resulting in a representative distribution
of pO2 values. The relative frequency of pO2 readings with
values ≤ 2.5 mmHg, ≤ 5.0 mmHg and ≤ 10.0 mmHg as
well as mean and median pO2 were calculated to asses the
biological and clinical relevance of oxygenation measure-
ment [30].
Statistical methods
Data are summarized by calculating relative frequencies,
as well as suitable measurements of location and varia-
tion. The degree of linear relationship between different,
polarographically measured parameters of tumor
hypoxia, CPD, TP and the FDG-, and FMISO-PET param-
eters investigated by computing Pearson correlation coef-
ficients and displayed graphically using scatter plots.
All statistical analyses were performed using the
SPSS®12.0 statistical analysis software package.
Results
Color Duplex Sonography
The interindividual range of mean color pixel density in
the investigated lymph nodes was between 2.4% and
16.4% (mean = 8.1%; SD = 2.4%). The average TP was
0.065 cm/s with a range from 0.012 cm/s to 0.173 cm/s
and a SD of 0.051 cm/s. A mean number of 8.0 (range: 5–
16; SD = 4.4) recorded slices per measurement were eval-
uated.
Positron-Emission-Tomography
Mean and maximum SUV of FMISO (average FMISOSU-
Vmean = 1.69, SD = 0.40; average FMISOSUVmax = 1.98, SD =
0.50) and FDG (average FDGSUVmean = 8.13, SD = 3.45;
average FDGSUVmax = 9.79, SD = 4.41) as well as tumor-to-
muscle ratios of FMISO (averageFMISOT/M = 1.57, SD =
0.34) and tumor-to-blood ratios of FMISO (average FMI-
SOT/B = 1.13, SD = 0.25) were calculated for the total
tumor regions.
Polarographic pO2 measurement
The average median pO2 was 12.5 mmHg (range: 0.1–
41.1 mmHg; SD = 10.3 mmHg). The average mean pO2
was 17.6 mmHg (range: 8.8–36.0 mmHg; SD = 7.3
mmHg). The mean proportion of pO2 values ≤ 2.5 mmHg
was 29.3% (range: 0.0–58.5%; SD = 18.4%), of values ≤
5.0 mmHg 38.4% (range: 7.0–73.6%; SD = 18.1%) and of
values ≤ 10.0 mmHg 48.9% (range: 13.0–78.7%; 18.2%).
Correlations
In order to detect possible relations between the different
relevant polarographically measured parameters of tumor
hypoxia, FMISOT/M, FMISOT/B, CPD and TP, we calculated
the Pearson correlation coefficient. Correlations are listed
in Table 1. To emphasize relevant correlations (r>0.4)
bold numbers were used. Only a slight association
between FMISOT/B and the hypoxic fraction ≤ 2.5 mmHg
could be detected. There was no relevant correlation
between FMISOT/B and the other polarographically, as
well as sonographically, measured parameters. There was
also no relevant association between TP and the hypoxic
fractions ≤ 2.5 mmHg as well as ≤ 5.0 mmHg. When
graphically analyzing the observed correlations through
an evaluation of the corresponding scatter plots (Figure
1), there were two patients (patient1; patient2) with obvi-
ously low color pixel density, and mean/median pO2 val-
ues based on inhomogeneous distribution of the different
hypoxic fractions with a high percentage of readings ≤ 10
mmHg and low percentage of readings ≤ 2.5 or ≤ 5.0
mmHg.
In addition there were two patients (patient3; patient4)
with apparent discrepancy between FMISO uptake and
pO2-polarography. Re-evaluation of these patients
revealed small, mostly necrotic lymph node metastasesPage 4 of 9
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case with margining high perfused vessels. After exclusion
of these outliers, the absolute value of the corresponding
Pearson correlation coefficients increased clearly as
shown in Table1 in the right upper columns.
There was no relevant association between mean or max-
imum FDG uptake and the different polarographic- as
well as the CDS parameters with an absolute value of the
Pearson correlation coefficient ranging between 0.056
and 0.241. There was only a moderate association
between FMISOT/B and FDGSUVmax with a Pearson correla-
tion coefficient of 0.403. No relevant correlation between
FMISOSUVmax/mean and CPD/TP or the polarograhpic
parameters could be detected. Figure 2 shows the corre-
sponding results of pO2 polarography, CDS, FDG and
FMISO PET in a normoxic and a hypoxic tumor.
Discussion
Results of preclinical and clinical investigations during the
last ten years have confirmed that tumor hypoxia precedes
malignant progression by several mechanisms, including
an increased expression of transcription factors and gene
products involved in tumor progression and induction of
genomic instability. In those investigations, the transcrip-
tional factor HIF-1 has emerged as a major regulator of
adaptive processes (including angiogenesis) that can sup-
port tumor cell survival, proliferation, invasion, and
tumor spread. It has also been shown that hypoxia can
enhance malignant progression and increase aggressive-
ness through clonal selection [31]. Numerous different
approaches have been made in order to identify hypoxia
in tumors for clinical use [13].
One standard method for quantifying hypoxia, although
it was partly controversially discussed in literature, has
been electrode measurement of tumor oxygen tension
[4,24,28,29]. Several studies have shown that lower oxy-
genated tumors are more radio resistant [8,11]. This was
recently shown in an international multi-centre study of
397 patients with squamous cell carcinomas of the head
and neck [22], identifying pre-treatment tumor hypoxia as
an indicator for poor overall survival after radiotherapy.
Although it represents a mixture of intra- and intercellular
pO2 of 30 to 50 cells in front of the probe and not a direct
measurement of intracellular oxygenation, it enables an
estimation of radio biologically relevant intracellular oxy-
genation. This could be proved by the use of comet assay
and pO2 polarograph in anaplastic R3327-AT Dunning
prostate tumors, resulting in high correlations between
mean pO2 and mean comet moment as a parameter of
overall strand break induction [26]. Applying pO2 histog-
raphy, an evaluation of intratumoral oxygenation hetero-
geneity, but not of spatial information is possible. As an
invasive method it is confined to superficial, well accessi-
ble tumors or lymph node metastases. Evaluating the dif-
ferent methods for determination of tumor oxygenation,
we found only slight to moderate correlations between
Table 1: Correlations between different relevant polarographically measured parameters of tumor hypoxia, FMISO PET, CDS and 
FDG PET data based oxygenation values
≤2.5 mmHg ≤5.0 mmHg ≤10.0 
mmHg
Median 
pO2
Mean pO2 FMISOT/M FMISOT/B CPD TP FDGSUVmax FDGSUVmean
≤2.5 mmHg r = 0.746 r = 0.476 r =-0.735 r = -0.355 r = 0.302 r = 0.276
N 36 20 20 28 16 20 20
≤5.0 mmHg r = 0.934 r = 0.757 r = 0.478 r =-0.786 r =-0.527 r = 0.161 r = 0.123
N 36 36 20 20 28 16 20 20
≤10.0 mmHg r = 0.765 r = 0.903 r = 0.703 r = 0.435 r =-0.788 r =-0.604 r = 0.021 r = -0.013
N 36 36 36 20 20 28 16 20 20
Mean pO2 r =-0.610 r =-0.768 r =-0.902 r =-0.589 r = -0.278 r = 0.720 r = 0.607 r = 0.167 r = 0.174
N 36 36 36 36 20 20 28 16 20 20
Mean pO2 r =-0.485 r =-0.676 r =-0.837 r = 0.923 r =-0.582 r = -0.272 r = 0.576 r = 0.508 r = 0.166 r = 0.161
N 36 36 36 36 36 20 20 28 16 20 20
FMISOT/M r = 0.558 r = 0.551 r = 0.462 r =-0.413 r = -0.376
N 22 22 22 22 22 24
FMISOT/B r = 0.401 r = 0.396 r = 0.342 r = -0.215 r = -0.200 0.557
N 22 22 22 22 22 24 24
CPD r =-0.475 r =-0.537 r =-0.662 r = 0.590 r = 0.468 r =-0.503 r = -0.270
N 31 31 31 31 31 18 18 32
TP r = -0.145 r = -0.303 r =-0.592 r = 0.604 r = 0.519 r =-0.509 r = 0.004 r = 0.784
N 18 18 18 18 18 9 9 18 18
FDGSUVmax r = 0.241 r = 0.101 r = -0.056 R = 0.205 r = 0.219 r = 0.159 r = 0.403 r = 0.105 r = 0.179
N 22 22 22 22 22 24 24 18 9 24
FDGSUVmean r = 0.238 r = 0.087 r = -0.062 R = 0.193 r = 0.193 r = 0.108 r = 0.329 r = -0.077 r = 0.103 r = 0.982
N 22 22 22 22 22 24 24 18 9 24 24
Correlations after exclusion of outliers in the marked right upper columns of the table; relevant correlation marked by bold numbers; r = Pearson 
coefficient of correlation; N = number of correlated measurements.Page 5 of 9
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ble parameters. When analyzing the differences in correla-
tion through an evaluation of the scatter plots (Figure 1),
we were able to identify four outliers representing the lim-
itations of the different methods.
Comparing the parameters of pO2 polarography and CPD
there were two patients (patient 1 and 2) with low mean
and median pO2 values based on inhomogeneous distri-
bution of the different hypoxic fractions. There was a high
percentage of readings ≤ 10 mmHg and a low percentage
of readings ≤ 2.5 or ≤ 5.0 mmHg. CPD or TP only deliver
a mean value of tumor vascularisation or perfusion. The
method is therefore unable to reproduce any heterogene-
ity of tumor oxygenation resulting in a decreased correla-
tion between CPD or TP and the hypoxic fractions ≤ 2.5
and ≤ 5.0 mmHg.
As an endpoint for reporting FMISO PET data, we used the
ratio between radioactivity in the tumor and reference tis-
sue, consisting of muscle tissue and blood as suggested by
Chapman et al. and Kubota et al. [1,16]. It could be
shown that the tumor uptake of FMISO was constant
between 30 min and 2 h and that the tumor to blood and
tumor to muscle FMISO uptake ratios were stable 2–4 h
after injection suggesting some retention mechanisms of
FMISO within the tumor but not within any normal tissue
[16]. Analyzing patient 3, this patient revealed a mostly
necrotic lymph node metastasis with only a small amount
of margining vital, hyperperfused tumor tissue. Although
we tried to ensure electrode measurements in vital tumor
tissue by the use of computed tomography guidance, an
overestimation of hypoxic fractions by pO2 polarography
must be expected. Rejecting central necrotic tumor parts
from CDS evaluation, we found good correlation between
CDS and FMISO parameters. Patient 4 also showed an
apparent discrepancy between FMISO uptake and pO2-
polarography. This patient had a lymph node metastasis
with a necrotic part and a part with vital tumor tissue (Fig-
ure 3). In this case, it was possible to realize CT controlled
pO2 polarography and CDS measurement in the vital
tumor part. Because of the small vital tumor volume and
due to the limited spatial resolution of PET data, a repre-
sentative measurement of tumor oxygenation by FMISO
was not possible. In contrast to CDS parameters with dis-
From left to right: transaxial FDG PET-, transaxial FMISO PET-, CDS- and ransaxial CT scans in two different patientsigure 2
From left to right: transaxial FDG PET-, transaxial FMISO 
PET-, CDS- and transaxial CT scans in two different patients. 
A:with a normoxic tumor (pO2 ≤ 2.5 mmHg = 13.0%, pO2 ≤ 
5.0 mmHg = 15.1%, pO2 ≤ 10.0 mmHg = 17.0%, median pO2 
= 36.2 mmHg, mean pO2 = 41.1 mmHg; CPD = 12.05%; 
FDGSUVmax = 17.84, FDGSUVmean = 14.80; FMISOT/M = 1.31, 
FMISOT/B = 1.07). B:with a hypoxic tumorB (pO2 ≤ 2.5 mmHg 
= 37.7%, pO2 ≤ 5.0 mmHg = 48.8%, pO2 ≤ 10.0 mmHg = 
58.1%, median pO2 = 5.5 mmHg, mean pO2 = 17.7 mmHg; 
CPD = 2.71%; FDGSUVmax = 9.34, FDGSUVmean = 8.00; FMI-
SOT/M = 1.60, FMISOT/B = 0.88). 1/2 = distance measure-
ments for the guidance of the polarographic needle electrode
Scatter plots visualizing type of association between selected polarographic parameters (median pO2, hypoxic fraction ≤ 2.5 mmHg and ≤ 5.0 mmHg) and color pixel density (CPD) aswell as FMISO t mor o muscle rati  (FMISOT/M) after 2 h (→ arked ou liers). L ft r phs: scatter p ots using al  avail-able d ta v lue . Right g a h : corresponding catter p otsft r exc usi n of marked outli rs ident fi d in th  left graphFigure 1
Scatter plots visualizing type of association between selected 
polarographic parameters (median pO2, hypoxic fraction ≤ 
2.5 mmHg and ≤ 5.0 mmHg) and color pixel density (CPD) as 
well as FMISO tumor to muscle ratio (FMISOT/M) after 2 h 
(→ marked outliers). Left graphs: scatter plots using all avail-
able data values. Right graphs: corresponding scatter plots 
after exclusion of marked outliers identified in the left graph.
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there were moderate to good correlations between the dif-
ferent hypoxic fractions and FMISOT/M. But a decrease in
the degree of linear association between FMISOT/M and
mean as well as median pO2 could be detected. Using 3H-
MISO and a monolayer cell sandwich system with V79
and 9 L cell lines, Hlatky et al. could detect a systematic
decrease in the standard deviation of grains per cell when
they examined populations of cells further away from the
nutrient and oxygen source [9]. An accumulation of MISO
below 10.0 mmHg and an inverse relationship of MISO
uptake to decreased polarographically measured pO2
could be expected. But even this accumulation of MISO
below 10 mmHg may explain the lower correlation
between FMISOT/M or FMISOT/B after 2 h and mean or
median pO2, because of high pO2 values leading to higher
mean or median pO2, which cannot be visualized by
FMISO PET. This fact was confirmed by different parame-
ters of pO2 polarography showing only slight to moderate
correlations between the fraction of pO2 values ≤ 2.5
mmHg and the mean or median pO2.
The hypothesis that tumor hypoxia has an effect on glu-
cose metabolism is mainly based on experimental data
using human cancer cell lines and clinical results and is
discussed controversially [2,15,21,34]. Although hypoxia-
inducible factor 1 alpha (HIF-1α) is a major regulator of
tumor cell adaptation to hypoxic stress, increasing the
expression of glycolytic enzymes and proteins [31,33], the
FDG uptake was not predictive for tumor hypoxia as
assessed by pO2-polarography in our series of patients.
Examining blood flow-metabolic relationships, the
results analyzing perfusion parameters and glucose
metabolism are contradictory [17,20]. According to the
progress in tumor molecular genetics in the last decade,
biological rational for association of these factors are
given by p53 oncogene. The p53 oncogene is known to
promote tumor angiogenesis and glucose metabolism.
Tumor cells use the tumor suppressor p53, which is usu-
ally modified by mutations to debilitate cell cycle con-
trols, to activate hexokinase gene transcription in
particular the Type II isoform. This induces the capacity of
tumor cells, at least in part, to catabolise glucose at high
rates [18,19]. Mutant p53 might also stimulate tumor
angiogenesis, indirectly by augmenting the tumor cell
proliferation and directly, by up regulating angiogenic fac-
tors and down regulating angiogenic inhibitors in the
same way [32]. In addition a significant association of
intratumoral micro vessel density and p53 protein over
expression was described in head-and-neck carcinoma
[7]. However, we were not able to show an association
between the vascularisation or tumor perfusion seen in
CDS images and glucose metabolism as shown by FDG
PET parameters, reflecting the problem of adverse effects
such as flow based supply of oxygen and glucose, p53
gene based stimulation of tumor angiogenesis and glu-
cose metabolism as well as hypoxia induced HIF-1α
expression of glucose transport proteins and hexokinase.
It reflects that tumor hypoxia is caused by innumerable,
multifactorial, partly contradictory interacting causes and
effects complicating detection of therapy relevant hypoxia
Outlier patient 4, transaxial FDG PET- (A), transaxial FMISO PET- (B), CDS- (C) d tr nsaxial C  (D) scans (pO2 ≤ 2.5 mmHg = 43.0%, pO2 ≤ 5.0 mmHg = 53.0%, pO2 ≤ 10.0 mmHg= 71.5%, median pO2 = 3.7 mmHg, mean pO2 = 8.8 m Hg; CPD = 2.96%; FDGSUVmax = 4.80, FDGSUVmean  4.55; -SOT/M = 1.19, FMIS T/B = 1.11). 1/2 = distance measure-ents for he guidance of the polarogr phic n edle electrodeFigure 3
Outlier patient 4, transaxial FDG PET- (A), transaxial FMISO 
PET- (B), CDS- (C) and transaxial CT (D) scans (pO2 = 2.5 
mmHg= 43.0%, pO2 = 5.0 mmHg = 53.0%, pO2 = 10.0 mmHg 
= 71.5%, median pO2 = 3.7 mmHg, mean pO2 = 8.8 mmHg; 
CPD = 2.96%; FDGSUVmax = 4.80, FDGSUVmean = 4.55; FMI-
SOT/M = 1.19, FMISOT/B = 1.11). 1/2 = distance measure-
ments for the guidance of the polarographic needle 
electrode.Page 7 of 9
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BMC Cancer 2007, 7:113 http://www.biomedcentral.com/1471-2407/7/113by the use of clinical examinations. Nevertheless those
examinations may enable the transfer of simplified infor-
mation from cellular micro cosmos into clinical practice.
Conclusion
Applying CDS for the evaluation of two factors mainly
influencing relevant tumor hypoxia as vascularisation
(CPD) and perfusion (TP), an estimation of average tissue
oxygenation without quantification of oxygenation heter-
ogeneity was possible. The later could be realized by the
FMISO parameters especially by FMISOT/M after 2 h. It
facilitated spatial information, but showed its limits in
small tumor lesions caused by spatial resolution of the
PET scanner. Although FDG uptake may increase under
hypoxic conditions, it could not reliably differentiate
hypoxic from normoxic tumors.
Clinical relevance of polarographic determination of
tumor oxygenation was elucidated in several clinical stud-
ies. But recently the emphasis has been on the potential
use of non-invasive approaches. CDS and FMISO PET for
estimation of therapy relevant tumor hypoxia represent
different non invasive approaches for analysis of tumor
hypoxia. But each of these approaches is methodologi-
cally limited. Consequently clinical potential must be
substantiated in a prospective study, including uniform
treatment modalities in order to be more than only bricks
in the puzzle of therapy relevant tumor hypoxia.
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